Conditions: Epilepsy
Keywords: Eslicarbazepine acetate Epilepsy Oxcarbazepine
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 13
Healthy volunteers: yes

Brief summary:
To investigate the pharmacokinetics of a single 900 mg oral dose of BIA 2-093 and a single 900 mg oral dose of Oxcarbazepine in healthy volunteers and to assess the tolerability of a single 900 mg dose of BIA 2-093 and Oxcarbazepine.

Detailed description:
Single centre, open label, balanced randomised, two-way crossover study in 12 healthy volunteers. The study consisted of 2 periods separated by a washout period of 7 days or more. On each of the study periods the volunteers received either a single 900 mg oral dose of BIA 2-093 or a single 900 mg oral dose of Oxcarbazepine.

Arms:
arm 1: Period 1 - Subjects recieved 900 mg of BIA 2-093 Period 2 - Subjects recieved 900 mg of oxcarbazepine arm 2: Period 1 - Subjects recieved 900 mg of oxcarbazepine Period 2 - Subjects recieved 900 mg of BIA 2-093

Interventions: intervention 1: BIA 2-093 intervention 2: Oxcarbazepine
Intervention descriptions: intervention 1: Tablets containing BIA 2-093 in doses of 300 and 600 mg intervention 2: Tablets containing 300 mg and 600 mg of Trileptal®

Protocol document: